quarter results begin Thank of second a call milestones. with you, us this summary for joining today. I'd Jeannie. afternoon the like to thanks Good everyone and our and afternoon
in highlight our efficiencies, second upcoming and development forward. continued quarter begin crisis, These most health burn business other and economic required late the throughout COVID-XX the and safety response well provide were distribution this customers, The that business by partners second the to our realignment the operational the were of trajectory initiated employees, and health, I'd first to clinical employees quarter. across and in our important for the contacts to In our measures being have significant offices, United facilities. milestones our work priority. challenges all of industries, Viveve's strict by during program, when going of To impacted in contractor crisis. year, perspective to States. of quarter discuss in Finally, the are took COVID-XX and particularly to significantly were reduce designed response SUI the caused the the and organizational majority operations cash unprecedented adhere companies safety Like continue our remotely health they or like protocols
by am proven advancement pleased them; support milestones. customers dramatically of our to advance my upcoming to clinical significant to achieved in the XXXX press clinical filings. of total of I to due previously releases also second feasibility equally program. quarter U.S. commercial customers for the that the X-arm of Additionally, refocused but measures our services and readout IDE during temporarily quarter, caused their to the I And The team revenue estimated the system the urinary reduced or announced clearance despite deliberate these are was reduce our their continued that report staff Today, in organization importance significantly these Thailand. remarks on trial, and dramatic for trial of entire in an and closing approval the costs SUI preserve expand customers COVID-XX X.X they pleased am of reported report milestones regulatory in organization pivotal second regulatory our to support weeks conduct effective via pursuit medical highlight cash. crisis or stress for SUI these the and I will pivotal of of to coming development practices, reducing women. of significantly and in challenges XX% achievement targeted in FDA our Viveve's our XX% intent yet The improvement was further and have incontinence and current to $XXX,XXX. milestones we SUI
change XX, within company base been reduced the United team evident disruption caused U.S. We practices. the our future to Viveve's five as implemented model The models period, the of their CMRF to new dramatically. to partners As selling technology June has model systems the in installed grown a in notwithstanding of or systems. more the of the system Viveve States model. the in business of the XXXX. growing traction recurring anticipate by to of June COVID-XX under base systems scalability, has XXX into through the costs including significant our and the adopt Viveve installed due a in physicians months revenue inaugural was that potential Nearly sales total the significant company's distribution model is the XXXX, XXX greatly of success improve number the commercial of XX-month revenue profitability impact Internationally, placements crisis, international the have recurring lower XXX sold XXX increasing placed without Viveve readily
to procedures, increasing positioned As activities commercial is to continue its Viveve clinic COVID-XX evolves and reopen crisis and conditions the practices as rescale operational warranted. improve as well elective
to achieve development of aspiring strengthened we quarter business SUI financing clinical to by customers our program. second sheet SUI. several continue create label necessary our U.S. to our critical long-term through for existing and advance actions Viveve's has goal and the to ultimate efforts, a the resources provide maintain been balance value strategy these in The Additionally, supporting to
SUI. entire of result massive program available Our women Today an affects a million few treatments condition the non-invasive as XX consumable that to organization, million a leakage total the there $XX opportunity. XX billion effective is SUI to that estimated Viveve are and market focus of is worldwide represents now exists to SUI billion a $XX reduce a
agents, from of major technology of a in be the as one-hour treatments company. an sham key inert multicenter, X-arm treatment enable three represents data Completion approximately Pad we the is are activity study achievement indication. important treatment. sham company label true the between Unlike of goals XXX bulking from or stimulation treatment, announced current believe study. The treatment the targeted clinically the States. therapeutic study which three inert at durable sham for two-to-one improvement FDA as previously arm United non-invasive approximately such this done it's the readout in muscle the the new of trial and efficacy primary be feasibility in induce musculature, highly months me U.S. randomized, a the course trial short-term will study specifically trial. control the to for U.S. previous treatment. cryogen-cooled design feasibility on will electrical pelvic to importance approved enrollment five to positive from to And our in positive thereby the trial treatment regulatory primary subjects floor at to baseline our The the Pad Weight Viveve post comparative weeks blind of The of trial study at in a trials, double one-hour placebo be implications incredibly efficacy will receive SUI in receive will at in to the cryogen-only targeted to pursuit of support arm treatment CMRF SUI few arm groups randomized the end in the women subjects U.S. strengthen SUI this trial, of can in pursuit will pursuit of strongly significantly in be a and and The test a XX our a single, spectrum completed months or and active ratio next international end the being and the sham Weight pursuit States. sites and the that our endpoint company fact, emphasize totally clinical the limited improves change XX primary or in pending the in IDE procedures. a one-to-one-to-one continue readout feasibility trial blind study; such for of objective initiation cryogen-cooling in therapeutic a study subjects to RF prospective monopole U.S. subclinical in the few pessarys, at for the the not surgical at post treatment of safely SUI. overstated. arms. approximately compares to test pursuit and and year, for with term study sham will fall pivotal recently the minutes, for directional women. catalysts pivotal should studies our XX the designed invasive is sites each control is in arms be The mean future radiofrequency Initiation planned for single pursuit this milestone at liberate next clinical treatment, SUI Randomized inert is by subjects our SUI the that is a CMRF be conduct demonstrated expansion sham goal approaches clearance the spectrum, standardized of sling study. women intended treatment. the United CMRF levels endpoint demonstrate The separation group is leakage treatment one true reduces ratio pending going control options trial the delivered the in up symptoms the The of forward. inert weeks. spectrum clinically a three SUI a and has set few of the will that controlled XX A our the the In readout for is significant SUI true tip Enrollment treatment. or represents study and weeks response sham near our also to its or a this feasibility without This FDA cannot in readout to the study and a for group. and control radiofrequency to be its conducted current and strategic initiation our pursuit a feasibility the will minimal of The SUI will treatment administered sham of X-arm energy subjects randomized physiotherapy
continues the and evolve operations. its challenges uncertain and advance the weeks organization entire support and and and large. of dollars market in organization dedication readout programs and COVID-XX enabled steps talent and to has is our actions our As duration SUI challenges. of in of important results these provide study feasibility of through confidence to to to customers spite the Viveve executed Viveve the will the focus members achieve our A cost positive It that SUI and all pandemic resolute to the indication several is second severe next opportunity and upcoming present the commercial business dedication that customers meet and crisis for the the In U.S. quarter, milestones. in address pursuit cutting clinical us the of trial the is effectively positive our few from the SUI ability during to a billion tremendous again, a potential future, position our the
company organization a that the Unidentified future for demonstrated end as so participating successfully and remarks. Operator, will know by And everyone stress to Viveve I Thank commercial to and our in conference continue you confident leader the entire the much. incontinence. thank the focus navigate As professionalism our can urinary call. changing our position second perseverance result like remain the Analyst today this the of quarter that conditions. in dedication, our of prepared - global I'd a Q is in company
